Mainz Biomed Secures $6 Million in Private Placement, Shifts Focus to Pancreatic Cancer Detection

Mainz Biomed N.V., a molecular genetics diagnostic company, has announced a $6 million private placement designed to enhance its financial position and pivot its focus towards pancreatic cancer detection in the U.S. This strategic movement aims to bolster the company's stability and its pursuit of growth opportunities.

On February 13, 2026, Mainz Biomed initiated a securities purchase agreement with investor David Lazar, who also assumes the role of Chairman of the Board of Directors. The private placement will transpire in two $3 million tranches, utilizing Convertible Non-Redeemable Preferred Stock. The initial tranche concluded on February 13, while the second is anticipated before April 15, pending required approvals.

Mainz Biomed is exploring potential sales of its colorectal cancer screening assets and winding down operations in Germany. These actions are designed to cut expenses and redirect focus to U.S. operations amid discussions with potential buyers.